Abstract
We report on the antileukemic activity of homoharringtonine (HHT) in T-cell acute lymphoblastic leukemia (T-ALL). We showed that HHT inhibited the NOTCH/MYC pathway and induced significantly longer survival in mouse and patient-derived T-ALL xenograft models, supporting HHT as a promising agent for T-ALL.
© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Harringtonines* / pharmacology
-
Harringtonines* / therapeutic use
-
Homoharringtonine* / pharmacology
-
Homoharringtonine* / therapeutic use
-
Humans
-
Mice
-
Mice, Inbred NOD
-
Mice, SCID
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / metabolism
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
-
Proto-Oncogene Proteins c-myc* / genetics
-
Proto-Oncogene Proteins c-myc* / metabolism
-
Receptors, Notch* / antagonists & inhibitors
-
Receptors, Notch* / metabolism
-
Signal Transduction* / drug effects
-
Xenograft Model Antitumor Assays*
Substances
-
Homoharringtonine
-
Harringtonines
-
Receptors, Notch
-
Proto-Oncogene Proteins c-myc
-
MYC protein, human